Search results for "Embolisation"

showing 8 items of 8 documents

Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma

2017

Abstract Background Transarterial chemoembolisation is the standard of care for intermediate stage (BCLC B) hepatocellular carcinoma, but it is challenging to decide when to repeat or stop treatment. Here we performed the first external validation of the SNACOR (tumour Size and Number, baseline Alpha-fetoprotein, Child-Pugh and Objective radiological Response) risk prediction model. Methods A total of 1030 patients with hepatocellular carcinoma underwent transarterial chemoembolisation at our tertiary referral centre from January 2000 to December 2016. We determined the following variables that were needed to calculate the SNACOR at baseline: tumour size and number, alpha-fetoprotein level,…

AdultAged 80 and overMaleCarcinoma HepatocellularHepatocellular carcinomaLiver Neoplasms610 MedizinKaplan-Meier EstimateSNACORMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282Magnetic Resonance ImagingTreatment OutcomeTransarterial chemoembolisation610 Medical sciencesBiomarkers TumorHumansFemaleChemoembolization TherapeuticTomography X-Ray ComputedAgedNeoplasm StagingResearch Article
researchProduct

Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma

2015

Summary What is known and objective Drug eluting beads (DEBs) theoretically improve the efficacy and safety of transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Nonetheless, their economic profile has not been assessed. Our retrospective before/after study aimed to compare efficacy, safety and economic profile of two strategies of TACE without (Period 1) or with the possibility of using DEBs (Period 2). Methods All HCC patients treated by TACE in our hospital between March 2006 and May 2013 were included. Economic analyses were performed from the French Public Health Insurance point of view according to the French Diagnosis-Related Group prospective payment system an…

AdultMalesafetymedicine.medical_specialtyCarcinoma HepatocellularCost effectivenesschemoembolisationCost-Benefit AnalysisAntineoplastic AgentsTreatment failureDrug CostsEthiodized OilInternal medicinemedicineOverall survivalHumansPharmacology (medical)Chemoembolization Therapeuticcost-effectivenessAgedRetrospective StudiesPharmacologyAged 80 and overDrug CarriersDrug eluting beadsPublic health insurancebusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseasePrognosisMicrospheres3. Good healthSurgerySurvival RateTreatment OutcomeMedian timeDoxorubicinHepatocellular carcinoma[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyFemaleProspective payment systembusinessIdarubicin
researchProduct

Imaging-guided interventions modulating portal venous flow: Evidence and controversies

2021

Portal hypertension is defined by an increase in the portosystemic venous gradient. In most cases, increased resistance to portal blood flow is the initial cause of elevated portal pressure. More than 90% of cases of portal hypertension are estimated to be due to advanced chronic liver disease or cirrhosis. Transjugular intrahepatic portosystemic shunts, a non-pharmacological treatment for portal hypertension, involve the placement of a stent between the portal vein and the hepatic vein or inferior vena cava which helps bypass hepatic resistance. Portal hypertension may also be a result of extrahepatic portal vein thrombosis or compression. In these cases, percutaneous portal vein recanalis…

HepatologyGastroenterologyInternal MedicineImmunology and AllergyALPPS associating liver partition and portal vein ligation for staged hepatectomy transjugular intrahepatic portosystemic shunt BSG British Society of Gastroenterology EASL European Association for the Study of the Liver FLR future liver remnant HE hepatic encephalopathy NCBA N-butyl cyanoacrylate PH portal hypertension PVE portal vein embolisation PVR portal vein recanalisation TIPS transjugular intrahepatic portosystemic shunt Portal vein interventions TACE trans-arterial chemoembolization portal vein recanalization RCT randomised controlled trial portal vein embolization portal hypertension image guidedJHEP Reports
researchProduct

Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients.

2012

Abstract Purpose The aim of our study was to assess the results and cost of a treatment strategy involving transarterial chemoembolisation with drug eluting beads (DEB-TACE) in patients with unresectable non-metastatic hepatocellular carcinoma (HCC). Patients and methods This study included all patients treated with DEB-TACE in our hospital between January 2009 and December 2010. All patients received DEB-TACE on demand and were evaluated after each session. Results Twenty-one patients received an average of 1.3 sessions. The median time to treatment discontinuation and median progression-free survival was 181 days and 295 days, respectively. Toxicity caused treatment discontinuation in thr…

Malemedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomaCostResultDrug Delivery SystemsTransarterial chemoembolisationOn demandmedicineHumansRadiology Nuclear Medicine and imagingIn patientChemoembolization TherapeuticAgedRetrospective StudiesAged 80 and overRadiological and Ultrasound TechnologyDrug eluting beadsbusiness.industryLiver NeoplasmsGeneral MedicineDirect costMiddle Agedmedicine.diseaseDrug eluting beadsMicrospheresSurgeryDiscontinuationTreatment OutcomeMedian timeHepatocellular carcinomaCosts and Cost AnalysisFemaleProspective payment systembusinessDiagnostic and interventional imaging
researchProduct

Chemoembolization for hepatocellular carcinoma : optimization of the procedure

2011

With 700,000 deaths in 2008, hepatocellular carcinoma is the 3rd most common cause of cancer-related death worldwide. Transarterial chemoembolization is the standard treatment for intermediate-stage hepatocellular carcinoma. This intraarterial treatment is performed by injecting an anticancer drug carried by ethiodized oil or by drug-eluting beads and followed by the occlusion of the artery when ethiodized oil is used. Median survival of patients remains < 2 years, and there is no consensus about the optimal treatment regimen. The aim of our work was to improve the efficacy of transarterial chemoembolization in optimizing the anticancer drug and its carrier.We have demonstrated that idarubi…

Microsphères d’embolisation[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyEthiodized oilLipiodolAgent anticancéreuxHepatocellular carcinoma[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyAntineoplastic agentsChimioembolisationChemoembolizationCarcinome hépatocellulaire
researchProduct

Iatrogenic lumbar artery pseudoaneurysm after lumbar transpedicular fixation: Case report

2019

Only a few cases of iatrogenic lumbar injury have been reported in the literature. A 58-year-old male with severe back pain was admitted to our department. The patient was qualified for the transpedicular stabilization with interbody fixation at L4/L5 and L5/S1 levels. On the first day after surgery, the patient was mobile and reported significant pain relief. He was discharged the same day. After 2 weeks, the patient returned with severe right lower abdominal pain and radicular pain in his right leg. He was administered to the Neurology Department where the presence of a lumbar muscle hematoma and lumbar artery pseudoaneurysm were discovered. He was transferred to the Vascular Surgery Depa…

lcsh:R5-920medicine.medical_specialtybusiness.industryiatrogenic pseudoaneurysmVascular complicationsCase Reportposterior lumbar interbody fusion complicationGeneral Medicinemedicine.diseaseSurgerytranspedicular fixation03 medical and health sciencesPseudoaneurysm0302 clinical medicineLumbarmedicine.arterymedicineSevere back pain030212 general & internal medicinelcsh:Medicine (General)businessTranspedicular fixationendovasular embolisation030217 neurology & neurosurgeryLumbar arteriesSAGE Open Medical Case Reports
researchProduct

Anomalous origin of bronchial arteries in patients with cystic fibrosis: therapeutic implications for embolisation.

2006

Bronchial artery embolisation (BAE) is an accepted method of controlling haemoptysis in patients with cystic fibrosis. However, anomalous origin of the bronchial arteries, documented in anatomical and angiographic studies, makes the procedure more difficult and increases the number of recurrences. Clinical records and films from three patients affected by cystic fibrosis with haemoptysis, in which the origin of the bleeding vessels was considered anomalous, out of a total of seven patients who underwent BAE, were reviewed. In two patients the source of bleeding was identified from, respectively, the left and the right internal mammary artery and in one from the left thyrocervical trunk. All…

medicine.medical_specialtyBronchial arterybusiness.industryEmbolisationRight internal mammary arterymedicine.diseaseCystic fibrosisSurgeryCystic fibrosimedicine.arterymedicineSurgeryLeft thyrocervical trunkIn patientRadiologybusinessBronchial arteryClinical recordMinimally invasive therapyallied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
researchProduct

Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation - authors’ reply

2012

medicine.medical_specialtyHepatologybusiness.industryGeneral surgeryGastroenterologymedicine.diseaseGastroenterologyInternal medicineHepatocellular carcinomahepatocellular carcinoma transarterial chemoembolisationmedicinePharmacology (medical)Liver dysfunctionbusinessAlimentary Pharmacology &amp; Therapeutics
researchProduct